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Abstract: 
Background and aims Severe pre- and acute postoperative pain have been associated with 
development of chronic postoperative pain. Chlorzoxazone (a muscle relaxant) has been suggested 
to enhance acute postoperative pain recovery but the lack of larger randomized controlled trials 
have however questioned the continued use. Despite this, chlorzoxazone is still used for acute 
postoperative pain management following total knee or hip replacement (TKR or THR). The 
currentrandomized, double blinded, placebo-controlled, parallel group, clinical trial aimed to assess 
the effect of chlorzoxazone for postoperative pain management following TKR or THR. 
Methods 393 patients scheduled for TKR or THR were included in the trial. Patients were assigned 
to 250mg chlorzoxazone three times daily for the first seven days postoperative or placebo. The 
primary outcome was pain after 5 meter walk assessed 24-hours postoperative. Secondary outcomes 
included, changes in preoperative pain at rest, worst pain in the last 24 hours, and Oxford Knee or 
Hip Score compared with 12 months follow-up. In addition, adverse events were assessed in the 
perioperative period. 
Results No significant differences were found for any of the outcome parameters after TKR or 
THR.  For neither TKR or THR no effects were demonstrated for pain after 5 meters walk 24-hours 
after surgery (P>0.313), or for any of the secondary outcomes (P>0.288) or adverse event (P>0.112) 
in the group receiving chlorzoxazone compared with placebo. 
Conclusions The current study demonstrated no analgesic effects of postoperative chlorzoxazone 
administration compared with placebo on acute or chronic postoperative pain 12 months following 
TKR and THR. 
Key words Total Knee Replacement, Total Hip Replacement, Chlorzoxazone, Muscel Relaxants, 
Postoperative Pain Management. 
  






Pain and reduced physical function are the main symptoms of osteoarthritis (OA). Total Knee 
Replacement (TKR) and Total Hip Replacement (THR) is the final treatment of the end-stage OA. 
The treatment is effective and produces long-lasting improvements of physical function and reduces 
pain for most patients.
1,2
 Despite this, up to 20% of TKR-patients, and up to 10% of THR-patients 
suffer from chronic postoperative pain after otherwise technically successful surgeries.
3–5
 
Despite the high number of surgeries performed
6
, and the expected increase in the future
7
, there is 
no consensus in the analgesic protocols after TKR and THR surgery.
8–11
 
Treatment of acute postoperative pain is a multimodal analgesic strategy that involves optimizing 
perioperative analgesia, reducing opioid-related adverse events and in general limiting the causes of 
chronic postoperative pain.
8–10,12–14
 Ideally, sufficient analgesia should be achieved using a 
synergistic effect of different drugs thus lowering the overall incidence of adverse effects. 
Severe pain in the acute postoperative phase has been associated with chronic postoperative pain
15
. 
Chlorzoxazone is a muscle relaxant that has been suggested to enhance acute postoperative pain 
recovery
16
, which thereby may reduce postoperative pain. 
Chlorzoxazone inhibits mono- and polysynaptic reflexes in the CNS,
17,18
 but the specific 
mechanism of action is not clear. A study by Van Tulder et al., 2003 suggested that chlorzoxazone 
may partly be associated with sedative effects due to the benzodiazepine derivative structure of 
chlorzoxazone.
16,17
 Placebo-designed clinical studies of chlorzoxazone's beneficial effect on 
heterogeneous groups of patients with spasticity, motor neuron syndromes, as well as muscle pain 
and spasm of peripheral musculoskeletal diseases have not been able to demonstrate any significant 
analgesic effect.
17
   Chlorzoxazone has also failed to show pain-relieving effect in the treatment of 
back pain.
17,19
 Further, chlorzoxazone has also been used in spine surgery, however limited effect in 





a large randomized controlled trial questioned the continued use.
20
  Despite this, chlorzoxazone is 
still routinely used for acute postoperative pain management following TKR and THR. 
The aim of this randomized, double blinded, placebo-controlled, parallel group, clinical trial was to 
investigate the effect of peri- and postoperative administration of chlorzoxazone on acute and 
chronic postoperative pain in patients scheduled for TKR and THR. 
2 Methods 
2.1 Study design and patients 
The study was approved by the Danish Medicines Agency, the regional ethics committee N-
20150024, and the Danish Data Protection Agency and was registered at EudraCT (2015-001214-
10) and www.clinicaltrials.gov (NCT02405104, April 1, 2015). It was conducted in accordance 
with Good Clinical Practice guidelines and the Helsinki Declarations, and was monitored by the 
Good Clinical Practice Monitoring Unit of Aalborg and Aarhus University Hospitals. 
Oral and written informed consent was obtained from all patients before participating in this single-
center, prospective, randomized, double blind, parallel-arm, placebo-controlled clinical study. 
Patients scheduled to undergo elective, unilateral primary TKR or THR were assessed for eligibility 
(by surgeons and project nurses) and recruited at a prescheduled (study independent) hospital visit 
for clinical examination preceding admission for surgery, at Aalborg University Hospital, Farsø, 
Denmark, between September 2015 and September 2016. Patients were excluded based on the 
following criteria age below 18, preoperative use of gabapentinoids, systemic glucocorticoids, 
opioids, anxiolytics, antiepileptics or antidepressants (within 4 weeks), history of bipolar affective 
disorder, alcohol or drug abuse, malignant condition, liver disease, body mass index >40 kg/m2, 
diseases affecting central or peripheral nerve function, history of dementia or other cognitive 
dysfunction, allergies towards the medicine to be tested, lack of ability to walk 5 meters, and 





pregnant or breastfeeding women. Further patients were excluded if there were perioperative 
complications, and any need of pain treatment apart from the standard. 
2.2 Randomization, blinding and study drug intervention 
Randomization, blinding procedures and study drug preparations were handled by a state-registered 
and certificated pharmacy, The Northern Denmark Regional Pharmacy, not otherwise involved in 
the trial. The patients were randomized in blocks of 10 (20 blocks) without the use of stratification 
variables. 
The study drug, chlorzoxazone 250mg (Klorzoxazon®; Takeda Pharma, Taastrup, Denmark), and 
placebo were prepared by the pharmacy as tablets identical in appearance. The dosage of the study 
drug was chosen by recommendation by the Danish Pharmaceutical Information and Takeda 
Pharma. 
The medication was self-administered, three times a day for 7 days, starting 2 hours preoperative, 
and thereafter at 8 AM, 4 PM and 10 PM on postoperative days 1 to 7. To facilitate drug 
compliance, the patients had to fill out a questionnaire twice a day.  After study completion, any 
remaining drugs were collected as control of compliance. 
2.3 Outcome measures and assessments 
The primary outcome was pain 24 hours after post surgery, measured as Pain after walking 5 meters 
with a walking aid. This was chosen because previous studies have argued that pain on movement 
exerts the most direct adverse impact on postoperative functional recovery.
21
 Twenty-four hours 
was chosen because almost all patients would be able to be mobilized at this time.
22
 The secondary 
outcomes were the patients functional level determined by Oxford Knee and Hip Score 7 days 
postoperative, and changes in pain at rest, and worst pain in the last 24 hours, comparing 
preoperative and 12 months postoperative scores. 





Baseline patient characteristics including preoperative pain were assessed at a hospital visit for 
general clinical examination preceding admission for TKR or THR. 
During admission, patients were asked to rate their VAS score with a VAS ruler by a project nurse 
at 4, 6, 24, 28, 32 and 48 hours after surgery. After discharge patients placed a cross on the VAS 
line printed in the diary at day 2 to day 7, day 14 and at 12 months follow-up. A 10 cm Visual 
Analog Scale (VAS) was used (0 = no pain and 10 = worst pain imaginable). 
Oxford Knee Score (OKS) or Oxford Hip Score (OHS) was assessed as baseline measure, and at 
day 2, 4, 7, 14 and at 12 months follow-up. The OKS and OHS are 12-item questionnaires assessing 
pain and function of the patient’s knee or hip. 
OKS answers were sub grouped into a functional component and a pain component. The patient 
scored each question (item) from 0 to 4, with 0 being the worst outcome and 4 being the best 
outcome. The functional component consists of item 2, 3, 7, 11 and 12. The pain component 
consists of item 1, 4, 5, 6, 8, 9 and 10. The summed scores of each subscale were then standardized 
to a range from 0 (worst) to 100 (best).
23,24
 
Likewise, each question in OHS was scored by the patient from 0 to 4, with 0 being the worst 




Other outcomes assessed during admission were opioid consumption, postoperative fatigue, 
dizziness, nausea and vomiting. Opioid consumption was measured in milligrams per day. If 
different kinds of opioids were used, the dose were converted to morphine milliequivalents. 
Postoperative fatigue was assessed at 6, 24, 32, and 48 hours after surgery. The 11-point numeric 
rating scale (NRS) was used (0 = no fatigue and 10 = worst fatigue imaginable; subjective rating by 
patients).
25
 Vomiting was assessed at 6, 24, 32, and 48 hours and registered as number of events 
since last recording. Dizziness and nausea were assessed at 6, 24, 32, and 48 hours and in the diary 





from days 2 to 6 each evening (before going to bed). The 4-point verbal rating scale was used (0 = 
no, 1 = mild, 2 = moderate and 3 = severe; subjective rating by patients). 
2.4 Anesthesia, surgery, and analgesia 
Surgery was performed under lumbar spinal anesthesia with bupivacaine 0.5%, 7.5mg (1.5ml) and 
optional supplemental propofol (1-5mg/kg/hour). Total knee replacement was performed using a 
midline skin incision and medial parapatellar arthrotomy. Total hip replacement was performed 
using the posterolateral approach. Both types of surgery were performed without application of 
surgical drains. TKR patients had Local Infiltration Anesthesia (LIA) with 100 mL 2% 
Ropivacain® during surgery, were as THR patients had no LIA. 
A basic analgesic regime was used consisting of slow release oral acetaminophen and celecoxib. 2 
hours preoperative, acetaminophen 2 g and celecoxib 400 mg were administered (together with the 
study drug); thereafter acetaminophen 2 g and celecoxib 200 mg were administered regularly at 8 
AM and 10 PM up to and including postoperative day 6. Study drug as described previously. 
Rescue analgesics (administered on demand as required if VAS >50 mm at rest) consisted of 
intravenous sufentanil 5mg (patients above 70 years) and 10 mg (patients below 70 years) in the 
post anesthesia care unit (PACU) and subsequently of oral morphine 10mg (patients above 70 
years) and 20 mg (patients below 70 years) at the ward and after discharge, up to a maximum of 4 
doses per 24 hours. In very few cases, other opioids (ketobemidone, oxycodone), and intravenous 
morphine were used due to resistant pain (administered on demand if VAS >50 mm at rest, for one 
hour after last opioid administration). During admission, nausea and vomiting were treated with 
ondansetron 4 mg. 
Patients followed a well-defined fast-track rehabilitation regime and were discharged to their homes 
according to routine functional discharge criteria.
22
 





2.5 Sample size calculation 
Estimated sample size for the primary outcome was calculated based on the results from Andersen 
et al. 2009 who assessed pain upon ambulation the first day after TKR and found a mean of 54 (SD: 
25) on a VAS (0-100).
14
 Thus, 50 patients in each group would allow the detection of a clinically 
relevant 30% difference in VAS pain after 5 meters walk 24 hours after surgery between 
Chlorzoxazone and placebo groups, at a 2-sided 5% significance level, and with a power of 90%. 
As to the secondary outcome, a 20% difference in OKS/OHS from preoperative to day 7 
postoperative was wanted, also at a 2-sided 5% significance level, and with a power of 90%. This 
requires 90 patients in each group. Therefore, we decided to include 400 patients (100 in each 




2.6 Statistical analysis 
Statistical analyses were performed in IBM SPSS Statistics (ver. 25, IBM Corporation, New York, 
USA), and we analyzed the outcome with the accessible measurements. 
Normal distribution was assessed using the Kolmogorov-Smirnov test. Normal distribution was 
accepted for baseline characteristics, and not accepted for primary and secondary outcomes, as well 
for the rest of the other outcomes. Between group differences were evaluated with independent 
sample t-test or the nonparametric Mann-Whitney U-test. Data are presented as mean and 95% 
confidence interval (95% CI), median (range) or frequencies, as relevant. P<0.05 was considered 
significant. All outcomes were Bonferroni corrected to account for multiple comparisons. 
3 Results 
From September 2015 to September 2016 a total of 944 patients had a TKR or THR in our hospital. 
551 of these did not meet the inclusion criteria for this study. The remaining 393 patients were 
screened and invited to participate in the study and were randomized into 4 groups. 





After randomization 198 were scheduled for TKR and 195 were scheduled for THR. In TKR group, 
100 patients were randomized to Chlorzoxazone group, and 98 patients to Placebo group. In THR 
group, 97 patients were randomized to Chlorzoxazone group, and 98 patients to Placebo group. 19 
patients were excluded after randomization, 13 scheduled for TKR, and 6 scheduled for THR 
(Figure 1). 
Baseline patient characteristics and preoperative data are presented in Table 1. The Placebo group 
demonstrated significantly better preoperative function in Oxford Knee Score (OKS) compared to 
the Chlorzoxazone group (P = 0.034), and the Chlorzoxazone group demonstrated significantly 
better preoperative in Oxford Hip Score (OHS) compare to the Placebo group (P=0.042). No other 
significant preoperative differences were found. Likewise, perioperative data and adherence to 
protocol were no significantly different between the groups. 
3.1 Pain after 5 meters walk 
No significant effect was found for primary outcome pain after 5 meters walk 24 hours 
postoperative for TKR (Bonferroni: P = 1.0) and THR (Bonferroni: P=1.0). However, a significance 
in pain after 5 m walk was found at 48 hours postoperative, favoring Placebo for TKA (Bonferroni: 
P= 0.048) (Table 2). 
3.2 Pain at rest and Worst pain for the last 24 hours 
No significant effect was found for the secondary outcome pain at rest and worst pain for the last 24 
hours (Table 3). 
3.3 Oxford Knee/Hip Score 
No significant effect was observed for Oxford Knee and Hip Scores within the first seven 
postoperative days (Bonferroni: P>0.12), nor at 12 months follow-up (Figure 2). 





3.4 Opioid consumption 
No significant difference in opioid consumption the first 7 days postoperatively was found, neither 
for Oral vs IV analgesia (Table 4). 
3.5 Other outcomes 
Also, no intervention effect was observed for any of the other outcomes measured during 
admission: postoperative fatigue (Bonferroni: P>0.24), dizziness (Bonferroni: P=1), nausea 
(Bonferroni: P>0.11), and vomiting (Bonferroni: P>0.21) (Table 1). 
4 Discussion 
The current randomized, placebo-controlled, parallel group clinical trial administered 
chlorzoxazone preoperatively and for the first 7 postoperative days after THR and TKR surgery, 
and demonstrated no significant reduction in pain during mobilization, pain at rest or in worst pain 
in the last 24 hours or any adverse events when compared with placebo. In addition, no effect was 
demonstrated in Oxford Knee or Hip Score within the first seven postoperative days when 
comparing chlorzoxazone to placebo. Finally, chlorzoxazone did not improve chronic postoperative 
pain at 12 months follow-up compared with placebo. 
4.1 Chlorzoxazone for postoperative pain management 
The effect of muscle relaxants on acute postoperative pain must be considered as uncertain, but may 
in some cases be indicated, most often as an adjunct to other forms of therapy, for example 
analgesics, anti-inflammatory agents, physiotherapy and training.
17,18
 
A systematic search of the literature revealed only one placebo-controlled trial of postoperative 
analgesic effect of chlorzoxazone. Nielsen et al.
20
 demonstrated no reduction in acute postoperative 
pain after a single 500 mg administration of chlorzoxazone after spine surgery for patients with 
moderate-to-severe pain, which is in line with present study. Furthermore a study by Kumar et al.
29
 
investigated the efficacy of the combination of thiocolchicoside and aceclofenac versus 





chlorzoxazone, aceclofenac and paracetamol in patients with acute lower backache associated with 
muscle spasm, and found the combination with chlorzoxazone inferior. 
No studies found, have investigated the analgesic effect of chlorzoxazone after knee or hip surgery. 
A placebo-controlled study by Gong et al.
30
 investigated the combined effect of administering 
Eperisone (a muscle relaxant) and celecoxib (COX-2 selective inhibitor) the first 2 postoperative 
weeks and found that the combination was superior to celecoxib alone and placebo on pain at rest, 
pain in ambulation and opioid use in the first 14 days postoperative. However, the reduction in pain 
is questionable for clinically relevance (a reduction on 0.74 in VAS), and furthermore, no long-term 
follow-up was available for comparison. 
Adverse reactions to chlorzoxazone are relatively few. The most frequently related adverse events 
are fatigue and dizziness (about 1-10% of patients).
16
 Adverse reactions are to some extent 
overlapping with the side effects that are related to the perioperative opioid treatment.
16
 It is 
therefore possible that the frequency of adverse events overall is reduced if chlorzoxazone is found 
to be analgesic (and opioid-sparing). 
The recommendations for postoperative pain management for both TKR and THR are: COX-2 
selective inhibitors or conventional NSAIDs in combination with acetaminophen, supplemented 
with weak or strong opioids.
9,10,31
 
However, present study demonstrated no reduction in adverse reactions, opioid consumption, or 
postoperative fatigue in the intervention group and can therefore not recommend perioperative 
administration of chlorzoxazone as treatment of acute postoperative pain following TKR and THR. 
Present study demonstrated a significant difference in Pain after 5m Walk after TKR measured 
among the patients still hospitalized 48 hours postoperative favorizing the Placebo group. However, 
no difference in baseline characteristic, nor any other difference in any other available measures are 
present including 1-year follow-up, beside that they were hospitalized more than 48 hours 





postoperatively. However, this finding is limited by missing data at 48 hours postoperatively, since 
approx. 70% of patients were discharged, which was not expected when this study was initiated. 
The strength of present study is that it is the first randomized, double blind placebo-controlled 
clinical trial investigating the analgesic effect of chlorzoxazone after TKR and THR. 
5 Conclusion 
The current clinical trial demonstrated no beneficial effects of chlorzoxazone giving perioperative 
and three times daily for 7 days postoperative on pain in the acute postoperative period or 
development of chronic posteoperative pain assessed after 12 months. Furthermore no effects were 
found on function. Based on these findings, it is thereby our recommendation not to use 
chlorzoxazone routinely for acute postoperative pain management following TKR and THR. 
However, a large sample multi-center study is recommended for confirmation of the findings of 
present study. 
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Figure 1 CONSORT: Flow of patients through the phases of the trail. TKR, Total Knee 
Replacement; THR, Total Hip Replacement. 
Figure 2 Development of Oxford Knee Score (OKS), function and pain, and Oxford Hip Score 
(OHS) from preoperative measurement to 12 months follow-up. 
Table 1 Pre- and perioperative demographics and baseline patient characteristics for the four groups 
and comparisons between them. * indicate significant difference favorizing Placebo. ** indicate 
significant difference favorizing Chlorzoxazone. 
(Data are expressed as count (percentage)
#
, mean (95% CI)
†
 or median (range)
¥
. Different kinds of 
opioids is converted to morphine milliequivalents. BMI, Body Mass Index. ASA score, American 
Society of Anesthesiologists Score. OKS, Oxford Knee Score. OHS, Oxford Hip Score. PACU, 
Post Anesthesia Care Unit.) 
Table 2 Mean (95%CI) VAS pain scores after 5 meters walk. VAS 4-48hours postoperative were 
assessed during admission. 12 months were assessed from the patient’s diary. * indicate significant 
difference in pain, favorizing Placebo. 
Table 3 VAS pain scores at rest, and VAS worst pain score for the last 24 hours. VAS 4-48 hours 
postoperative were assessed during admission. The rest were assessed from the patient’s diary. 
(Data are expressed as mean (95% CI).) 
Table 4 Consumption of opioids the first 7 days postoperatively. 1. and 2. postoperative day was 
assessed during admission. Morphine day 2 to 7 was assessed from the patient’s diary. Different 
kinds of opioids are converted to morphine milliequivalents. 
(Data are expressed as mean (95% CI). Mg, milligram. IV, Intravenous.) 
  







Table 1 Pre- and perioperative demographics and baseline patient characteristics for the four groups and comparisons between 















 69.2 (67.5-70.9) 70.5 (68.6-72.3) 0.130 68.1 (65.0-71.2) 65.7 (63.3-68.1) 0.617 
Male, n# 40 (42.6%) 42 (46.2%) 0.624 59 (62.2%) 61 (63.5%) 0.692 
Female, n# 54 (57.4%) 49 (53.8%)  36 (37.9%) 33 (36.5%)  
Weight, kg
†
 88.4 (84.7-92.0) 84.2 (80.9-87.5) 0.113 81.8 (78.4-85.1) 84.16 (81.1-87.2) 0.379 
Height, cm
†
 171.1 (169.2-173.0) 170.2 (168.3-172.2) 0.736 171.8 (168.9-174.7) 172.8 (171.2-174.4) 0.917 
BMI, kg/m2 
† 30.1 (29.0-31.2) 29.0 (28.0-29.9) 0.178 27.8 (26.7-28.9) 28.1 (27.2-29.0) 0.634 
Operation side: Right/Left# 48/46 54/37 0.260 51/44 48/46 0.720 
ASA score, I/II/III# 23/60/8 14/62/6 0.401 30/50/8 35/47/9 0.679 
Pain after 5m walk
†
 4.30 (3.7-4.9) 4.08 (3.5-4.6) 0.730 3.73 (3.2-4.3) 3.82 (3.3-4.3) 0.833 
Pain at rest
†
 3.58 (3.1-4.1) 3.50 (3.0-4.0) 0.806 3.27 (2.8-3.7) 3.52 (3.0-4.0) 0.516 
Worst pain the last 24 hours
†
 6.44 (6.0-6.9) 6.22 (5.7-6.7) 0.499 6.03 (5.6-6.5) 6.54 (6.0-7.0) 0.082 
OKS, function
†
 55 (51-58) 59 (56-63) 0.034* - -  
OKS, pain
†
 44 (41-47) 44 (41-48) 0.978 - -  
OHS
†
 - -  25.19 (6.3) 22.73 (7.4) 0.042** 
Duration of surgery, min
¥
 60 (63) 60 (91) 0.551 60.5 (86) 60 (80) 0.592 
Bleeding intraoperatively, ml
¥
 100 (1000) 100 (500) 0.695 400 (900) 350 (1300) 0.997 
PACU stay, min
¥
 80 (215) 85 (150) 0.982 67.5 (150) 60 (270) 0.668 
Sedation (0-10)       
6 hours postoperative
¥
 0 (5) 0 (5) 0.240 0 (8) 0 (6) 1.0 
24 hours postoperative
¥
 0 (4) 0 (4) 0.344 0 (8) 0 (6) 1.0 
32 hours postoperative
¥
 0 (10) 0 (10) 1.0 0 (4) 0 (4) 1.0 
48 hours postoperative
¥
 0 (2) 0 (6) 1.0 0 (2) 0 (1) 1.0 
Dizziness (0-3)       
6 hours postoperative
¥
 0 (3) 0 (3) 1.0 0 (3) 0 (3) 1.0 
24 hours postoperative
¥
 0 (2) 0 (3) 1.0 0 (3) 0 (3) 1.0 







 0 (1) 0 (3) 1.0 0 (3) 0 (3) 1.0 
48 hours postoperative
¥
 0 (1) 0 (2) 1.0 0 (3) 0 (2) 1.0 
Nausea (0-3)       
6 hours postoperative
¥
 0 (2) 0 (2) 1.0 0 (2) 0 (2) 1.0 
24 hours postoperative
¥
 0 (1) 0 (3) 1.0 0 (3) 0 (2) 1.0 
32 hours postoperative
¥
 0 (1) 0 (1) 0.112 0 (1) 0 (3) 1.0 
48 hours postoperative
¥
 0 (1) 0 (1) 1.0 0 (1) 0 (3) 1.0 
Vomiting, n       
No of patients vomiting 0-6h
#
 3 0 0.510 1 7 0.21 
No of patients vomiting 6-24h
#
 4 5 1.0 10 8 1.0 
No of patients vomiting 24-48h
#
 3 8 1.0 7 6 1.0 
Data are expressed as count (percentage)#, mean (95% CI)† or median (range)¥. Different kinds of opioids is converted to morphine 
milliequivalents. BMI, Body Mass Index. ASA score, American Society of Anesthesiologists Score. OKS, Oxford Knee Score. OHS, 
Oxford Hip Score. PACU, Post Anesthesia Care Unit. 
  







Table 2 Mean (95%CI) VAS pain scores after 5 meters walk. VAS 4-48hours postoperative were assessed during admission. 12 
months were assessed from the patient’s diary. * indicate significant difference in pain, favorizing Placebo. 
 
  












Inclusion 4.30 (3.7-4.9) 76 4.08 (3.5-4.6) 76 1.0 3.73 (3.2-4.3) 82 3.82 (3.3-4.3) 82 1.0 
4 hours postoperative 3.33 (2.6-4.1) 42 2.86 (2.2-3.5) 38 1.0 3.70 (2.9-4.6) 28 3.18 (2.4-3.9) 20 1.0 
6 hours postoperative 4.09 (3.6-4.6) 73 3.62 (3.2-4.0) 68 1.0 3.94 (3.5-4.3) 63 4.10 (3.7-4.5) 63 1.0 
24 hours postoperative 3.83 (3.5-4.2) 93 3.73 (3.4-4.1) 90 0.940 3.32 (3.0-3.7) 94 3.03 (2.7-3.3) 89 0.313 
28 hours postoperative 3.57 (3.2-3.9) 93 3.54 (3.2-3.9 91 1.0 2.65 (2.4-2.9) 94 2.43 (2.2-2.7) 90 1.0 
32 hours postoperative 3.97 (3.4-4.5) 33 3.58 (3-1-4.1) 42 1.0 2.78 (2.3-3.2) 30 2.68 (2.1-3.2) 28 1.0 
48 hours postoperative 3.59 (3.0-4.1) 29 2.53 (2.1-3.0) 34 0.048* 2.38 (1.8-3.0) 24 2.37 (1.7-3.0) 27 1.0 
12 months follow-up 1.09 (0.7-1.5) 86 1.20 (0.8-1.6) 83 1.0 0.65 (0.4-0.9) 90 0.66 (0.4-0.9) 88 1.0 







Table 3 VAS pain scores at rest, and VAS worst pain score for the last 24 hours. VAS 4-48 hours postoperative were assessed during 
admission. The rest were assessed from the patient’s diary. 












Preoperative examination 3.58 (3.1-4.1) 94 3.50 (3.0-4.0) 87 1.0 3.27 (2.8-3.7) 94 3.52 (3.0-4.0) 90 1.0 
4 hours postoperative 2.72 (2.2-3.3) 94 2.25 (1.8-2.7) 91 1.0 3.06 (2.6-3.5) 94 3.21 (2.7-3.7) 94 1.0 
6 hours postoperative 3.16 (2.7-3.6) 93 2.53 (2.2-2.9) 91 1.0 3.19 (2.8-3.6) 95 3.07 (2.7-3.5) 94 1.0 
24 hours postoperative 2.13 (1.8-2.5) 94 1.80 (1.5-2.1) 90 1.0 1.72 (1.4-2.0) 95 1.49 (1.2-1.8) 94 1.0 
28 hours postoperative 1.72 (1.4-2.1) 94 1.62 (1.3-1.9) 91 1.0 0.92 (0.7-1.1) 95 0.92 (0.7-1.2) 93 1.0 
32 hours postoperative 1.91 (1.4-2.5) 36 1.65 (1.2-2.1) 44 1.0 0.95 (0.5-1.4) 31 1.13 (0.7-1.6) 32 1.0 
48 hours postoperative 1.47 (0.8-2.1) 30 0.77 (0.4-1.1) 37 1.0 0.60 (0.2-1.0) 26 0.57 (0.2-0.9) 28 1.0 
Day 2 2.44 (2.0-2.9) 88 2.08 (1.7-2.4) 88 1.0 1.39 (1.0-1.7) 92 1.43 (1.2-1.7) 93 1.0 
Day 3 2.18 (1.8-2.6) 88 1.68 (1.4-2.0) 87 1.0 1.27 (1.0-1.6) 93 1.31 (1.1-1.6) 93 1.0 
Day 4 2.13 (1.8-2.5) 88 1.77 (1.4-2.1) 85 1.0 1.34 (1.1-1.6) 92 1.35 (1.1-1.6) 93 1.0 
Day 5 2.26 (1.9-2.7) 87 1.64 (1.4-1.9) 84 0.93 1.32 (1.0-1.6) 92 1.25 (1.0-1.5) 92 1.0 
Day 6 2.28 (1.9-2.7) 87 1.84 (1.5-2.2) 83 1.0 1.20 (0.9-1.5) 91 1.13 (0.9-1.3) 92 1.0 
Day 7 2.01 (1.7-2.4) 94 1.88 (1.5-2.2) 82 1.0 1.12 (0.9-1.4) 90 1.12 (0.9-1.3) 90 1.0 
Day 14 1.99 (1.5-2.4) 77 1.57 (1.2-1.9) 77 1.0 0.95 (0.7-1.2) 81 0.99 (0.8-1.2) 84 1.0 
12 months follow-up 0.91 (0.5-1.3) 88 1.05 (0.7-1.4) 85 1.0 0.53 (0.3-0.7) 90 0.48 (0.3-0.6) 88 1.0 












Preoperative examination 6.44 (6.0-6.9) 94 6.22 (5.7-6.7) 88 1.0 6.03 (5.6-6.5) 93 6.54 (6.0-7.0) 90 1.0 
Day 2 4.32 (3.8-4.8) 58 4.39 (3.7-5.1) 60 1.0 3.20 (2.6-3.8) 66 3.04 (2.5-3.6) 69 1.0 
Day 3 3.95 (3.3-4.6) 58 3.42 (2.8-4.1) 59 1.0 3.00 (2.4-3.6) 65 2.89 (2.4-3.4) 69 1.0 
Day 4 3.70 (3.1-4.4) 55 3.73 (3.1-4.4) 57 1.0 2.69 (2.2-3.2) 66 2.81 (2.3-3.3) 66 1.0 
Day 5 4.10 (3.5-4.7) 57 3.36 (2.7-4.0) 57 1.0 2.62 (2.1-3.1) 65 2.43 (2.0-2.9) 69 1.0 
Day 6 4.18 (3.5-4.9) 58 4.15 (2.6-5.7) 57 1.0 2.64 (2.1-3.2) 65 2.54 (2.0-3.1) 69 1.0 
Day 7 4.22 (3.7-4.8) 80 3.27 (2.8-3.8) 81 0.29 2.68 (2.2-3.2) 89 2.30 (1.9-2.7) 89 1.0 
Day 14 4.14 (3.5-4.8) 77 3.38 (2.8-4.0) 77 1.0 2.28 (1.8-2.8) 80 1.87 (1.5-2.3) 84 1.0 
12 months follow-up 1.46 (1.0-1.9) 87 1.60 (1.1-2.1) 83 1.0 0.93 (0.6-1.2) 89 0.68 (0.4-0.9) 87 1.0 
Data are expressed as mean (95% CI). 
 
  







Table 4 Consumption of opioids the first 7 days postoperatively. 1. and 2. postoperative day was assessed during admission. 
Morphine day 2 to 7 was assessed from the patient’s diary. Different kinds of opioids are converted to morphine milliequivalents. 






1. postoperative day, total mg morphine/day 55.6 (50.4-60.9) 57.7 (51.2-94.1) 59.9 (54.3-65.5) 54.3 (49.3-59.2) 
Oral vs IV mg morphine 51.5/3.5 56.5/2.1 56.6/3.3 52.0/2.3 
2. postoperative day, total mg morphine/day 24.8 (19.1-30.4) 28.1 (19.6-36.7) 12.0 (8.5-15.5) 12.9 (9.1-16.7) 
Oral vs IV morphine 24.7/0.1 28.0/0.1 12.0/0.0 12.9/0.0 
Morphine day 2 14.8 (11.7-18.0) 14.4 (11.5-17.3) 8.2 (5.6-10.8) 5.9 (3.3-8.5) 
Morphine day 3 11.1 (8.4-13.9) 10.1 (7.3-13.1) 6.3 (4.0-8.6) 4.2 (2.3-6.1) 
Morphine day 4 10.7 (7.9-13.5) 10.1 (7.2-12.9) 5.8 (3.8-7.8) 4.6 (2.6-6.7) 
Morphine day 5 12.3 (9.3-15.3) 10.1 (7.4-12.8) 5.2 (3.1-7.2) 4.2 (2.3-6.0) 
Morphine day 6 11.7 (8.8-14.5) 9.8 (7.2-12.3) 5.4 (3.6-7.2) 3.2 (1.4-4.9) 
Morphine day 7 5.9 (3.9-7.9) 6.2 (4.0-8.3) 2.4 (1.2-6.7) 2.9 (1.5-4.3) 
Data are expressed as mean (95% CI). Mg, milligram. IV, Intravenous. 
  





Figure 1 CONSORT: Flow of patients through the phases of the trail. TKR, Total Knee Replacement; THR, Total Hip Replacement. 
 
  





Figure 2 Development of Oxford Knee Score (OKS), function and pain, and Oxford Hip Score (OHS) from preoperative 
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